Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2024Pain and TherapyOpen Access

Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAndrew BlumenfeldCOPE Health SolutionsLMLászló MechtlerDent Neurologic InstituteLCLisa CookPain and Headache Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Blumenfeld et al. (2024) studied this question.

synapsesocial.com/papers/6a246c4473a8446529ba0971https://doi.org/10.1007/s40122-024-00649-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review2021 · 107 citations
  2. 2Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study2023 · 23 citations
  3. 3Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains2014 · 229 citations
  4. 4Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review2011 · 311 citations
  5. 5Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition2018 · 10,888 citations